- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Phase 1 clinical development of TU7710, bypassing agent for hemophilia with prolonged half life. | ||||||
| Recombinant Protein | Haemophilia A, B | recombinant coagulation factor VIIa | Phase 1 | TiumBio Co., Ltd. | RS-2023-00282592 | ||
| 2 | Phase 1a clinical trial and approval of IND for phase 1b/2a clinical trial of androgenic alopecia therapeutics using cell.penetrating RNAi gene regulation technology | ||||||
| Nucleic acid/Virus | Androgenetic alopecia | androgen receptor | Phase 1 | Olix Pharmaceuticals | RS-2023-00259300 | ||
| 3 | Phase 1 clinical trial of recombinant hyaluronidase ALT-BB4 | ||||||
| Recombinant Protein | N/A | Hyaluronidase | Phase 1 | Alteogen Inc. | HN22C0112 | ||